|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Denmeade SR and Isaacs JT: Development of
prostate cancer treatment: The good news. Prostate. 58:211–224.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlin BI and Andriole GL: The natural
history, skeletal complications, and management of bone metastases
in patients with prostate carcinoma. Cancer. 88 12
Suppl:S2989–S2994. 2000. View Article : Google Scholar
|
|
4
|
Bubendorf L, Schöpfer A, Wagner U, Sauter
G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns
of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol.
31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Investig. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miettinen PJ, Ebner R, Lopez AR and
Derynck R: TGF-beta induced transdifferentiation of mammary
epithelial cells to mesenchymal cells: Involvement of type I
receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyazono K: Transforming growth
factor-beta signaling in epithelial-mesenchymal transition and
progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 85:pp.
314–323. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown KA, Pietenpol JA and Moses HL: A
tale of two proteins: Differential roles and regulation of Smad2
and Smad3 in TGF-beta signaling. J Cell Biochem. 101:9–33. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsuzaki K: Smad phosphoisoform signaling
specificity: The right place at the right time. Carcinogenesis.
32:1578–1588. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moustakas A and Heldin CH: Non-Smad
TGF-beta signals. J Cell Sci. 118:3573–3584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reis ST, Pontes-Júnior J, Antunes AA,
Sousa-Canavez JM, Abe DK, Cruz JA, Dall'oglio MF, Crippa A,
Passerotti CC, Ribeiro-Filho LA, et al: Tgf-β1 expression as a
biomarker of poor prognosis in prostate cancer. Clinics (Sao
Paulo). 66:1143–1147. 2011.PubMed/NCBI
|
|
15
|
Wikström P, Stattin P, Franck-Lissbrant I,
Damber JE and Bergh A: Transforming growth factor beta1 is
associated with angiogenesis, metastasis, and poor clinical outcome
in prostate cancer. Prostate. 37:19–29. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun H and Taneja R: Stra13 expression is
associated with growth arrest and represses transcription through
histone deacetylase (HDAC)-dependent and HDAC-independent
mechanisms. Proc Natl Acad Sci USA. 97:pp. 4058–4063. 2000;
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Honma S, Kawamoto T, Takagi Y, Fujimoto K,
Sato F, Noshiro M, Kato Y and Honma K: Dec1 and Dec2 are regulators
of the mammalian molecular clock. Nature. 419:841–844. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y
and Yan B: The expression of antiapoptotic protein survivin is
transcriptionally upregulated by DEC1 primarily through multiple
sp1 binding sites in the proximal promoter. Oncogene. 25:3296–3306.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chakrabarti J, Turley H, Campo L, Han C,
Harris AL, Gatter KC and Fox SB: The transcription factor DEC1
(stra13, SHARP2) is associated with the hypoxic response and high
tumour grade in human breast cancers. Brit J Cancer. 91:954–958.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu Y, Sato F, Yamada T, Bhawal UK,
Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada
K, et al: The BHLH transcription factor DEC1 plays an important
role in the epithelial-mesenchymal transition of pancreatic cancer.
Int J Oncol. 41:1337–1346. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Q, Wu Y, Yoshizawa T, Yan X, Morohashi
S, Seino H, Kato Y and Kijima H: Basic helix-loop-helix
transcription factor DEC2 functions as an anti-apoptotic factor
during paclitaxel-induced apoptosis in human prostate cancer cells.
Int J Mol Med. 38:1727–1733. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Sato F, Kawamoto T, Fujimoto K,
Morohashi S, Akasaka H, Kondo J, Wu Y, Noshiro M, Kato Y and Kijima
H: Anti-apoptotic effect of the basic helix-loop-helix (bHLH)
transcription factor DEC2 in human breast cancer cells. Genes
Cells. 15:315–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Y, Liu Q, Yan X, Kato Y, Tanaka M,
Inokuchi S, Yoshizawa T, Morohashi S and Kijima H:
Podoplanin-mediated TGF-β-induced epithelial-mesenchymal transition
and its correlation with bHLH transcription factor DEC in TE-11
cells. Int J Oncol. 48:2310–2320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tomita K, van Bokhoven A, van Leenders GJ,
Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin
switching in human prostate cancer progression. Cancer Res.
60:3650–3654. 2000.PubMed/NCBI
|
|
25
|
Jennbacken K, Tesan T, Wang W, Gustavsson
H, Damber JE and Welén K: N-cadherin increases after androgen
deprivation and is associated with metastasis in prostate cancer.
Endocr Relat Cancer. 17:469–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jones E, Pu H and Kyprianou N: Targeting
TGF-beta in prostate cancer: Therapeutic possibilities during tumor
progression. Expert Opin Ther Targets. 13:227–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
